Novo Nordisk A/S (NVO) – Investment Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Novo Nordisk A/S (NYSE: NVO):

  • 9/19/2017 – Novo Nordisk A/S was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $55.00 price target on the stock. According to Zacks, “Novo Nordisk’s second-quarter results topped earnings, but missed revenue estimates. The company has a strong pipeline, primarily focusing on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone. The company has a strong presence in the Diabetes care market with a global value market share of 27%. The segment is driven by strong performance of drugs like Victoza, Tresiba, Saxenda and Xultophy among others. Novo Nordisk’s stock movement has outperformed the industry. However, we believe continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy will be partly offset by the impact of lower realized prices in the U.S., loss of exclusivity for products in hormone replacement therapy, intensifying competition within the diabetes and biopharmaceuticals markets and macroeconomic conditions in many markets under International Operations.”
  • 9/18/2017 – Novo Nordisk A/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Novo Nordisk’s second-quarter results topped earnings, but missed revenue estimates. The company has a strong pipeline, primarily focusing on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone. The company has a strong presence in the Diabetes care market with a global value market share of 27%. The segment is driven by strong performance of drugs like Victoza, Tresiba, Saxenda and Xultophy among others. Novo Nordisk’s stock movement has outperformed the industry. However, we believe continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy will be partly offset by the impact of lower realized prices in the U.S., loss of exclusivity for products in hormone replacement therapy, intensifying competition within the diabetes and biopharmaceuticals markets and macroeconomic conditions in many markets under International Operations.”
  • 9/13/2017 – Novo Nordisk A/S was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $55.00 price target on the stock. According to Zacks, “Novo Nordisk’s second-quarter results topped earnings, but missed revenue estimates. The company has a strong pipeline, primarily focusing on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone. The company has a strong presence in the Diabetes care market with a global value market share of 27%. The segment is driven by strong performance of drugs like Victoza, Tresiba, Saxenda and Xultophy among others. Novo Nordisk’s stock movement has outperformed the industry. However, we believe continued growth from Victoza and Tresiba as well as higher contributions from Saxenda and Xultophy will be partly offset by the impact of lower realized prices in the U.S., loss of exclusivity for products in hormone replacement therapy, intensifying competition within the diabetes and biopharmaceuticals markets and macroeconomic conditions in many markets under International Operations.”
  • 9/6/2017 – Novo Nordisk A/S was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating.
  • 8/12/2017 – Novo Nordisk A/S was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/31/2017 – Novo Nordisk A/S was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/24/2017 – Novo Nordisk A/S was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Novo Nordisk’s top line is driven by strong performance of products such as Victoza. Tresiba is also becoming one of the major contributors of revenue for the company. The company also received approval by the FDA for the Biologics License Application (BLA) for Rebinyn for the treatment of adults and children with hemophilia B and marketing authorization in Europe for the same for the treatment of adolescents and adults with haemophilia B. The company has a strong pipeline, primarily focusing on therapeutic proteins within insulin, GLP-1, blood clotting factors and human growth hormone. However, we are highly concerned about the patent expiry on some of the products in Novo Nordisk’s portfolio. Shares of Novo Nordisk have outperformed the Large Cap Pharmaceuticals industry year to date. Estimates have decreased lately ahead of the Q2 results. Novo Nordisk has mixed record of earnings surprises in the recent quarters.”

Novo Nordisk A/S (NYSE NVO) opened at 48.65 on Wednesday. The company has a market cap of $120.66 billion, a P/E ratio of 19.66 and a beta of 0.60. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $48.88. The stock’s 50 day moving average is $45.97 and its 200-day moving average is $41.13.

The business also recently declared an annual dividend, which was paid on Tuesday, August 29th. Stockholders of record on Monday, August 21st were issued a $0.336 dividend. This represents a dividend yield of 1.07%. The ex-dividend date was Friday, August 18th. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s dividend payout ratio is 36.44%.

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply